Share on LinkedInShare on LinkedIn

ARTICLE · 15 JANUARY 2015

Crunch Time: Compulsory Licensing In India

Pharmaceutical giant Bayer filed an appeal against the granting of a compulsory licence for Nexavar to Indian generic manufacturer Natco...

IndiaIntellectual Property

Pharmaceutical giant Bayer filed an appeal against the granting of a compulsory licence for Nexavar to Indian generic manufacturer Natco, but in March the IPAB dismissed the appeal, as R. Muralidharan and Ashima Katara report.

In a landmark ruling in one of the world's fastest growing pharmaceutical markets, the Intellectual Property Appellate Board (IPAB) of India upheld the compulsory licence granted to Natco Pharma Limited, an Indian drug manufacturer, for Bayer AG's Nexavar (sorafenib tosylate), an oncology palliative drug.

Natco approached Bayer for a voluntary licence which was refused. Natco then went ahead to file a compulsory licence application before the Controller of Patents on the grounds that the patentee had not worked the patent in India and the drug in question was being imported by the patentee even three years after the grant of patent; that the cost of Bayer's patented drug was Rs280,000 ($5,000) per month and because of the high cost,

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from